tremelimumab-actl | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,849 results for “tremelimumab-actl”

Trials

View all 1573 →

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

65 participants · First posted May 19, 2014

Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma (HCC) - A Phase II Trial (NEOTOMA)

10 participants · First posted Nov 19, 2024

Active, not recruiting

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

433 participants · First posted Aug 10, 2015

Drugs

View all 158 →

Tremelimumab(Imjudo, Tremelimumab AstraZeneca)

Conditions: Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)

tremelimumab + gefitinib

Durvalumab(Imfinzi)

Manufacturer: AstraZeneca

Conditions: Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer +5 more

Organizations

ACTA LABORATORIES, INC.

United States

ACTA Dental Research B.V.

Netherlands

ACT Biotech, Inc.

United States

News

View all 115 →

Imfinzi and Imjudo Combo Shows Unprecedented Survival in Liver Cancer

Durvalumab Demonstrates Improved Survival in Liver and Bladder Cancers

Novel Therapies Transform Treatment Landscape for Liver and Biliary Tract Cancers

Page 1 of 185